Real World Evidence Solutions Market by Component (Dataset (Pharmacy, Claims, Clinical, Patient), Services), End User (Medical Devices, Pharmaceuticals, Payers, Providers), Therapeutic Area (Cardiovascular, Oncology, Immunology) – 2019 to 2024

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: May 28, 2019
Clear
SKU: GMS414 Category:

The global market for real-world evidence is projected to reach USD 1412.4 million by 2024, growing over the forecast period at a CAGR of 13.9%. This market’s growth is driven primarily by the rising geriatric population, shifting from volume to value-based care, and delays in drug development.

Real World Evidence Solutions Market by Component (Dataset (Pharmacy, Claims, Clinical, Patient), Services), End User (Medical Devices, Pharmaceuticals, Payers, Providers), Therapeutic Area (Cardiovascular, Oncology, Immunology) - 2019 to 2024 1

Real World Evidence Solutions Market by Component (Dataset (Pharmacy, Claims, Clinical, Patient), Services), End User (Medical Devices, Pharmaceuticals, Payers, Providers), Therapeutic Area (Cardiovascular, Oncology, Immunology) - 2019 to 2024 2

Real World Evidence Solutions Market by Component (Dataset (Pharmacy, Claims, Clinical, Patient), Services), End User (Medical Devices, Pharmaceuticals, Payers, Providers), Therapeutic Area (Cardiovascular, Oncology, Immunology) - 2019 to 2024 3

Real World Evidence Solutions Market by Component (Dataset (Pharmacy, Claims, Clinical, Patient), Services), End User (Medical Devices, Pharmaceuticals, Payers, Providers), Therapeutic Area (Cardiovascular, Oncology, Immunology) - 2019 to 2024 4

Real World Evidence Solutions Market by Component (Dataset (Pharmacy, Claims, Clinical, Patient), Services), End User (Medical Devices, Pharmaceuticals, Payers, Providers), Therapeutic Area (Cardiovascular, Oncology, Immunology) - 2019 to 2024 5

Real World Evidence Solutions Market by Component (Dataset (Pharmacy, Claims, Clinical, Patient), Services), End User (Medical Devices, Pharmaceuticals, Payers, Providers), Therapeutic Area (Cardiovascular, Oncology, Immunology) - 2019 to 2024 6

Real World Evidence Solutions Market by Component (Dataset (Pharmacy, Claims, Clinical, Patient), Services), End User (Medical Devices, Pharmaceuticals, Payers, Providers), Therapeutic Area (Cardiovascular, Oncology, Immunology) - 2019 to 2024 7

Real World Evidence Solutions Market by Component (Dataset (Pharmacy, Claims, Clinical, Patient), Services), End User (Medical Devices, Pharmaceuticals, Payers, Providers), Therapeutic Area (Cardiovascular, Oncology, Immunology) - 2019 to 2024 8

1 Global Real World Evidence Solutions Market 
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Real World Evidence Solutions Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Real World Evidence Solutions Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Real World Evidence Solutions Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Real World Evidence Solutions Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Real World Evidence Solutions Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Real World Evidence Solutions Market – By Component (Market Size – &
million/billion)
8.1 Data Sets
8.2 Services

9 Global Real World Evidence Solutions Market – By Therapeutic Area
9.1 Oncology
9.2 Cardiovascular Disease
9.3 Neurology
9.4 Immunology
9.5 Others

10 Global Real World Evidence Solutions Market – By End-User
10.1 Pharmaceutical and Medical Device Companies
10.2 Healthcare Payers
10.3 Healthcare Providers
10.4 Other

11 Global Real World Evidence Solutions Market – By Geography (Market Size – &
million/billion)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 U.K
11.3.2 Germany
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Rest of APAC
11.5 Rest of the World
11.5.1 South America
11.5.2 Middle East
11.5.3 Africa

12 Global Real World Evidence Solutions Market – Entropy
12.1 New product launches
12.2 M&A’s, collaborations, JVs and partnerships

13 Global Real World Evidence Solutions Market Company Profile (Key Players)
13.1 Market Share, Company Revenue, Products, M&A, Developments
13.2 Iqvia
13.3 IBM
13.4 Pharmaceutical Product Development
13.5 Cognizant
13.6 Syneos Health
13.7 Parexel
13.8 Optum (A Subsidiary of United Health Group, Inc.)
13.9 Icon PLC
13.10 Oracle
13.11 Perkinelmer
13.12 Company 11 & more

14 Global Real World Evidence Solutions Market – Appendix
14.1 Sources
14.2 Abbreviations